Servier Pharmaceuticals
200 Pier Four Boulevard
Boston
MA
02210
United States
Tel: 888-788-1735
Website: http://www.servier.us/
Email: usinfo@servier.com
Servier is committed to serving patient needs. We work every day with passion for therapeutic progress to save and treat patients; It is our vocation. #WeAreServier
18 articles about Servier Pharmaceuticals
-
New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib's Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
11/18/2023
New data from Servier's clinical development program for vorasidenib in IDH-mutant diffuse glioma, presented at the 28th Annual Meeting of the Society for Neuro-Oncology in Vancouver, Canada, showed that vorasidenib reduced tumor growth as measured by a blinded independent radiology committee.
-
Servier Pharmaceuticals' Vorasidenib, acquired from Agios in a $1.8 billion deal, slowed the growth of a certain type of low-grade glioma by 61% in a Phase III trial.
-
Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)
3/14/2023
Servier announced today that the Phase 3 INDIGO clinical trial investigating vorasidenib in monotherapy for patients with residual or recurrent IDH mutant low-grade glioma met its primary endpoint of progression free survival (PFS) and the key secondary endpoint of time to next intervention (TTNI).
-
Servier and Taiho Oncology announced Tuesday that Lonsurf in combination with bevacizumab improved overall survival rates in patients with refractory metastatic colorectal cancer.
-
Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology
1/9/2023
Servier and Aqemia announce the extension of their new-molecule discovery collaboration on an undruggable therapeutic target in immuno-oncology.
-
TIBSOVO® (ivosidenib) Now Available from Onco360 for the Treatment of Adult Patients with IDH1-mutant Acute Myeloid Leukemia or Previously Treated, IDH1-mutant Metastatic Cholangiocarcinoma
9/15/2022
Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Servier Pharmaceuticals to be a specialty pharmacy partner for TIBSOVO® (ivosidenib), which is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with newly diagnosed acute myeloid leukemia.
-
Servier leverages Mission Bio's Tapestri® Platform to uncover AML resistance mechanisms in pivotal TIBSOVO® (ivosidenib) clinical trial
9/15/2022
Servier to present data at 12th Annual World Clinical Biomarkers & CDx Summit demonstrating the utility of single-cell DNA sequencing with Tapestri ® in clinical development.
-
Servier is poised to go to market soon after the Phase III trial of its proposed drug for leukemia closed with positive results.
-
Servier Joins Everest Climb to Fight Cancer Benefitting Fred Hutchinson Cancer Research Center
3/17/2022
Servier Pharmaceuticals, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced the company will join Luke Timmerman's trek to Everest Base Camp on March 23 through April 8, 2022, in Nepal.
-
Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline
1/18/2022
Olivier Laureau, President of Servier: "In 2020/21, the Servier Group continued to grow despite a difficult environment.
-
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in IDH1-Mutated Cholangiocarcinoma
8/25/2021
Servier Pharmaceuticals, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced today that the U.S. Food and Drug Administration (FDA) approved TIBSOVO®.
-
Servier Highlights Novel Approaches to Treating Cancer at the ASCO and EHA 2021 Annual Meetings
6/1/2021
Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced that data will be presented from multiple studies across its oncology portfolio during the 2021 American Society of Clinical Oncology Virtual Annual Meeting, June 4-8 and the European Hematology Association 2021 Virtual Congress, June 9-17.
-
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Cholangiocarcinoma
5/5/2021
Servier Pharmaceuticals, a leader in hematology, achieves first major milestone in the solid tumor category Company has grown U.S. oncology business by nearly 20% in the past two years
-
Servier was found guilty of manslaughter and deceptive marketing practice for its Mediator drug for weight loss. The Paris-based company was fined $3.12 million.
-
Servier and MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs.
-
The company bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios in a deal worth up to $2 billion.
-
Clinical Catch-Up: October 12-16
10/19/2020
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look. -
Back to the Drawing Board: Galapagos and Servier's Arthritis Knee Repair Drug Fails Phase II
10/16/2020
Galapagos NV and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet its primary endpoint in osteoarthritis knee repair.